What vital signs and intake‑output data should be obtained and recorded for a patient with chronic kidney disease?

Vital Signs and Intake/Output Monitoring for CKD Patients

For patients with chronic kidney disease, measure blood pressure using standardized office technique, monitor body weight daily at the same time, track fluid intake and output carefully, and assess serum creatinine and electrolytes (particularly potassium) at intervals determined by CKD stage.

Blood Pressure Monitoring

Target systolic blood pressure <120 mmHg using standardized office BP measurement for adults with CKD, when tolerated 1. This represents the most recent evidence-based target.

Standardized BP Measurement Technique

• Use oscillometric or manual devices with proper preparation 1
• Automated office BP (AOBP), either attended or unattended, is the preferred method 1
• Measure BP at every clinical contact 1
• Supplement office readings with out-of-office monitoring using ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) 1

Monitoring Frequency by CKD Stage

• Stage 3 CKD (eGFR 30-59): Every 6-12 months 1
• Stage 4 CKD (eGFR 15-29): Every 3-5 months 1
• Stage 5 CKD (eGFR <15): Every 1-3 months 1
• More frequent monitoring during medication titration 1

Critical Caveats

• Do not apply the <120 mmHg target to non-standardized BP measurements—this is potentially hazardous 1
• Consider less intensive BP targets in patients with frailty, high fall risk, limited life expectancy, or symptomatic postural hypotension 1
• Systolic BP variations are significantly associated with intradialytic hypotension in dialysis patients 2

Body Weight Monitoring

Measure body weight daily at the same time each day to assess fluid status and volume overload 1.

• Weight variation is significantly associated with intradialytic complications including cramps and hypotension 2
• Serial assessment guides diuretic dosing and fluid management 1
• Critical for detecting volume overload, which should be evaluated at every clinical contact 1

Fluid Intake and Output Documentation

Intake Monitoring

• Sodium intake should be <2 g/day (or <90 mmol/day, or <5 g sodium chloride/day) 1
• Total fluid intake requires careful tracking, though the relationship between plain water intake and CKD progression appears U-shaped—both very low (<0.5 L/day) and very high (>2.0 L/day) intake may accelerate progression 3
• Exception: Do not restrict sodium in patients with sodium-wasting nephropathy 1

Output Monitoring

• Measure urine output carefully during acute decompensation or diuretic therapy 1
• 24-hour urine collections assess volume and permit calculation of estimated urine osmolarity 3
• Decreasing urine output with hypoperfusion indicates critical illness requiring rapid intervention 1

Laboratory Monitoring

Serum Creatinine and eGFR

• Monitor at baseline and track changes to assess kidney function 1
• Frequency based on CKD stage (as above) 1
• Do not discontinue ACE inhibitors/ARBs for creatinine increases ≤30% in absence of volume depletion 1
• Monitor 7-14 days after initiation or dose changes of ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists 1

Serum Electrolytes (Particularly Potassium)

• Daily measurement during IV diuretic use or active medication titration 1
• Routine monitoring at clinical visits and 7-14 days after medication changes 1
• Essential when using ACE inhibitors, ARBs, mineralocorticoid receptor antagonists (risk of hyperkalemia), or diuretics (risk of hypokalemia) 1

Urinary Albumin Assessment

• Measure urine albumin-to-creatinine ratio (UACR) at least annually 1
• Monitor twice annually in patients with UACR >30 mg/g or eGFR <60 mL/min/1.73 m² 1
• Aim for ≥30% reduction in albuminuria to slow CKD progression in patients with UACR ≥300 mg/g 1

Additional Vital Signs

Temperature and Respiratory Rate

• Monitor for infections, which are common precipitating factors for acute HF and CKD decompensation 1
• Assess oxygen saturation and administer oxygen therapy for hypoxemia-related symptoms 1

Clinical Assessment of Perfusion

• Evaluate signs of systemic perfusion and congestion (supine and standing) 1
• Assess jugular venous pressure for elevated cardiac filling pressures 1
• Monitor for hypoperfusion with decreasing urine output 1

Common Pitfalls to Avoid

• Never use routine (non-standardized) office BP for treatment decisions—this lacks reliability and proper correlation with outcomes 1
• Do not stop renin-angiotensin system blockade for minor creatinine elevations (≤30%) without evidence of volume depletion 1
• Avoid applying general population BP targets to measurements obtained without standardization 1
• Do not overlook volume status assessment—clinical evaluation of fluid overload should occur at every encounter 1